Core Insights - Biogen Inc. announced upcoming presentations on dapirolizumab pegol (DZP), an anti-CD40L drug candidate for systemic lupus erythematosus (SLE), at the ACR Convergence 2025 [1][2] - The presentations will cover efficacy results across multiple endpoints, including disease activity, flares, fatigue, joint pain, and quality of life, along with preclinical data on placental transfer [1][4] Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on innovative science to develop new medicines and create shareholder value [7] - The company emphasizes a deep understanding of human biology and aims to deliver first-in-class treatments [7] Product Development - Dapirolizumab pegol is in Phase 3 clinical development for SLE, developed in collaboration with UCB [6][2] - It is one of only three biologics to report positive Phase 3 data in a global SLE study, with the primary endpoint met after 48 weeks [2][4] - Ongoing studies include the PHOENYCS FLY trial, which continues to evaluate the drug's efficacy [2][6] Presentation Details - Presentations at ACR will include various poster sessions focusing on quality of life improvements, adverse outcomes in reprotoxicity studies, and fatigue and pain management in SLE patients [3][5] - Specific poster presentations are scheduled for October 26-28, 2025, detailing results from Phase 3 trials [3][5]